Allakos announced positive Phase 1 results in patients with severe allergic conjunctivitis. Patients administered AK002 reported a 78% median improvement in ocular symptoms by Allergic Conjunctivitis Symptom Score and a 71% median improvement in physician assessed signs and symptoms using the Ocular Symptom Score. In addition, patients suffering from comorbid atopic dermatitis, asthma and allergic rhinitis, despite treatment with currently available therapies, reported improvements in their symptoms while receiving AK002.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.